LSKB Still Upbeat On Rivoceranib Despite ANGEL Failure In Late-Line Gastric Cancer
Executive Summary
LSKB's rivoceranib has missed its endpoint in a Phase III trial in gastric cancer, but the company remains hopeful it will still be able to get FDA approval of the VEGFR-2 inhibitor in this setting, possibly helped by a small additional trial, although there will be a delay. Studies in other potential indications are also ongoing.
You may also be interested in...
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.